Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
63%(5 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_3
4
44%
Ph phase_1
1
11%
Ph phase_2
4
44%

Phase Distribution

1

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
4(44.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(8)
Terminated(1)

Detailed Status

Completed8
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
88.9%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 24 (44.4%)
Phase 34 (44.4%)

Trials by Status

completed889%
terminated111%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_2

HPA Axis Study in Adults

NCT01408511
completedphase_2

HPA Axis Study in Japanese Adults

NCT01407510
completedphase_2

Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis

NCT01289431
completedphase_3

Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery

NCT01230125
terminatedphase_3

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery

NCT01298752
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT01408511Phase 2

HPA Axis Study in Adults

Completed
NCT01407510Phase 2

HPA Axis Study in Japanese Adults

Completed
NCT01289431Phase 2

Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis

Completed
NCT01230125Phase 3

Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery

Completed
NCT01298752Phase 3

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery

Terminated
NCT01591655Phase 3

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Completed
NCT01591161Phase 3

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Completed
NCT01359787Phase 2

Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)

Completed
NCT01736462Phase 1

Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9